S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
S&P 500   5,081.22 (+0.23%)
DOW   38,891.64 (-0.15%)
QQQ   438.20 (+0.67%)
AAPL   180.15 (-0.70%)
MSFT   409.81 (+0.51%)
META   489.23 (+1.08%)
GOOGL   137.15 (+0.56%)
AMZN   175.03 (+1.08%)
TSLA   200.37 (-0.83%)
NVDA   793.23 (+2.14%)
NIO   5.66 (+4.24%)
AMD   191.06 (+8.22%)
BABA   74.03 (-0.75%)
T   16.99 (+0.18%)
F   12.41 (+0.89%)
MU   89.91 (+0.22%)
CGC   3.28 (-2.38%)
GE   156.03 (+0.27%)
DIS   111.33 (+0.48%)
AMC   4.30 (-13.83%)
PFE   26.78 (-0.96%)
PYPL   60.24 (-0.02%)
XOM   104.48 (+0.15%)
NASDAQ:EYES

Second Sight Medical Products (EYES) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$4.11
$13.05
52-Week Range
N/A
Volume
36,800 shs
Average Volume
132,982 shs
Market Capitalization
$54.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

EYES stock logo

About Second Sight Medical Products Stock (NASDAQ:EYES)

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.


EYES Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Vivani Medical Inc
See More Headlines
Receive EYES Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Second Sight Medical Products and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
6/29/2020
Today
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Electromedical Equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:EYES
Employees
15
Year Founded
N/A

Profitability

Net Income
$-8,920,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.38 million
Book Value
$4.80 per share

Miscellaneous

Free Float
6,935,000
Market Cap
$54.38 million
Optionable
Optionable
Beta
2.55
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Scott Dunbar (Age 64)
    Acting Chief Exec. Officer
    Comp: $301.39k
  • Mr. Edward Jonathon Sedo (Age 66)
    Acting Chief Accounting Officer, Principal Financial Officer & Controller
    Comp: $199.18k
  • Mr. Edward David Randolph (Age 64)
    Chief Operating Officer
    Comp: $366.44k
  • Gunnar Bjorg
    Founder
  • Ms. Lisa M. Wilson (Age 57)
    Founder & Pres of In-Site Communications and Investor Relations for Second Sight














EYES Stock Analysis - Frequently Asked Questions

How were Second Sight Medical Products' earnings last quarter?

Second Sight Medical Products, Inc. (NASDAQ:EYES) posted its quarterly earnings results on Monday, June, 29th. The medical device company reported ($1.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by $0.48.

When did Second Sight Medical Products' stock split?

Second Sight Medical Products shares reverse split on the morning of Friday, August 19th 2022. The 1-3 reverse split was announced on Friday, August 19th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split.

What is Will McGuire's approval rating as Second Sight Medical Products' CEO?

5 employees have rated Second Sight Medical Products Chief Executive Officer Will McGuire on Glassdoor.com. Will McGuire has an approval rating of 57% among the company's employees. This puts Will McGuire in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Second Sight Medical Products own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), VBI Vaccines (VBIV), Shopify (SHOP), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Ekso Bionics (EKSO) and OPKO Health (OPK).

When did Second Sight Medical Products IPO?

(EYES) raised $32 million in an initial public offering on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC acted as the underwriter for the IPO.

This page (NASDAQ:EYES) was last updated on 2/29/2024 by MarketBeat.com Staff